precision medicine has the potential to change the way we think about, identify and manage cancer care. the impact on both clinical research and patient care will grow as our understanding and technologies improve and precision medicine and biomarkers will transform the delivery of cancer care to benefit both patients and cancer care systems.

the european commission defined [2015] personalised medicine as “a model of medicine that uses the molecular profile [phenotypes and genotypes] for tailoring the right therapeutic strategy for the right person at the right time, and | or to determine the predisposition to disease and | or to deliver timely and targeted prevention” working in collaboration, we can greatly improve access to precision medicines and biomarkers, with a flexible regulatory framework that accelerates access, encouraging policies that invest in and support the use of precision medicines and biomarkers, and educating on the potential effectiveness and efficiency precision medicine and biomarkers can make in our health care system.

precision medicine is rapidly having an impact on how drugs are discovered and developed; how patients are diagnosed and treated; and how health care delivery is channeling its resources to maximize patient benefits. precision medicine is having an important impact in clinical care, the great potential to improve the quality of patient care and to help contain health care costs and it should be directed at individual patients through the practice of medicine rather than through regulatory action.

media release


montréal. november 2. 2020– throughout the month of november, the cancer collaborative in collaboration with the european cancer patients coalition [ECPC] will highlight the growing role that precision medicine plays in oncology through the CRACKING THE CANCER CODE campaign.

the premise of precision oncology is to treat patients based on the molecular characteristics of the tumour and employs the use of diverse strategies in cancer care from the use of targeted therapies to application of comprehensive genomic profiling, such as next generation sequencing [NGS] to guide patient care.


ECPC_Biomarker-Infographic [download PDF]
blog posts

what are biomarkers

understanding cancer - cancer is a disease that is characterized by abnormal cell process involving uncontrolled cell growth and proliferation that alters normal cell behaviour. the genetic alterations within the cancer cells will be manifested by the release of...

understanding cancer

cancer is a collection of related diseases that can occur almost anywhere in the body and is characterized by abnormal cell process involving uncontrolled cell growth and proliferation that alters normal cell behaviour. there are over 100 types of cancers, and in all...

car-t. hype or hope

a few weeks ago, I attended the canadian agency for drugs and technologies in health [CADTH] symposium in edmonton, AB. the opening plenary discussion was on 'the hope and hype' in healthcare. your perspective on this, of course, depends on how you’re looking at...



If you haven’t already done so - don’t forget to register for @LymphomaCanada Annual Patient Conference taking place 14.10.2021 register here

we work hard in the background to make sure all canadians have accessing not only to CAR-T but all the therapies they need and sometimes we get recognized for the work we do. thank you

Load More...